Oral formulation based on a previously established association of sulodexide with flavonoids for the treatment of chronic venous insufficiency and the prevention of its complications
The oral composition of sulodexide and flavonoids, particularly diosmin, effectively treats and prevents CVI complications by synergistically reducing vascular hyperpermeability and restoring venous tone, outperforming single active ingredients in efficacy.
Patent Information
- Application Number
- JP2024533953
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-07
- Filing Date
- 2022-11-17
- Publication Date
- 2024-11-21
AI Technical Summary
Current treatments for chronic venous insufficiency (CVI) are inadequate in preventing complications and effectively managing the disease across various stages, particularly in conserving and invasive management, and there is a need for more effective therapeutic strategies.
A composition comprising sulodexide and one or more flavonoids, particularly diosmin, hesperidin, and troxerutin, administered orally, which synergistically address microvascular changes and venous tone issues in CVI.
The combination of sulodexide and flavonoids effectively reduces vascular hyperpermeability, inflammatory processes, and restores venous tone, accelerating ulcer healing and improving the clinical prognosis of CVI, with enhanced efficacy compared to single active ingredients.
Smart Images

Figure 2024543612000005 
Figure 2024543612000006 
Figure 2024543612000007
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for oral use comprising as active ingredients sulodexide and one or more flavonoids in the treatment of venous diseases or disorders or conditions associated with or caused by said venous diseases, in particular in the treatment of chronic venous insufficiency (CVI) and / or the prevention of its complications. [Background technology]
[0002] Vascular disease is one of the most prevalent diseases in the world, and chronic venous insufficiency (CVI) of the lower extremities is one of the diseases with a higher incidence and prevalence in women.
[0003] CVI is an "outflow disease" that occurs as a result of structural abnormalities involving the venous wall, either dilated (varicose) or obstructive, with the latter including deep vein thrombosis (DVT), superficial venous thrombosis (SVT), and post-thrombotic syndrome, among other manifestations. The clinical presentation of CVI is highly diverse, and the intensity and severity of the disease can be highly variable, determining the development of changes at the aesthetic level alone (reticular veins, telangiectasias, etc.) to conditions of considerable tissue damage (e.g., lipodermatosclerosis, trophic ulcers).
[0004] Several factors, such as predisposing hereditary-constitutional factors or precipitating factors such as sedentary lifestyle, overweight, hormones and pregnancy, come together in determining the development of CVI. Such factors can trigger complex physiopathological mechanisms that cause the venous system to malfunction by impairing its operation as a centipetal draining organ through damage to the venous and / or lymphatic drainage system. This phenomenon can occur after abnormalities of the segmental valve structure (e.g. post-thrombotic syndrome with destruction of the valve system) and dilation of the venous wall (e.g. varicose veins), whereby the valve capacity is no longer sufficient.
[0005] From the insufficiency of the segmental valves, various initial syndromes can develop, as well as secondary varicose veins (post-thrombotic syndrome) with insufficiency of the deep venous circulation. The resulting venous hypertension is the basis of all congestive lymphatic pictures, including especially all areas with greater gravity involvement (e.g. the perimaleolar area), and interstitial absorption and more general pathological changes can develop, ranging from edema to thrombotic and phlebitis processes, lipodermatosclerosis, and trophic lesions.
[0006] CVI is characterized by variations in parietal tension and venous pressure that are responsible for alterations in the homeostasis of the microvascular tissue, with the resultant release of inflammatory mediators and increased vasal permeability. In recent years, much progress has been made in the understanding of CVI physiology and changes at the cellular or ultrastructural level that induce the gross abnormalities found clinically. At the heart of the pathological process is found the inflammatory phenomenon, which involves the passage of leukocytes, firstly by adhesion and then by transudative hemorrhage in the subendothelial layer, via alterations in the normal endothelial coating (glycocalyx) of the venous wall due to congestion, shear stress, venous hypertension and blood hyperviscosity. The leukocytes thus activated release a series of "inflammatory" factors, which initiate the chemotactic process that amplifies the inflammatory disease (phlogosis) itself and the further release of substances that mediate local "harmful" substances. Such inflammatory processes coexist with parallel hemodynamic phenomena (reflux, venous hypertension, interstitial absorption) which, finally, synergistically determine a common clinical outcome in terms of symptoms (heaviness and heat, swelling, pain) and signs (edema, flushing, varicose veins, skin and subcutaneous inflammation, phlebitis).
[0007] Once an accurate anamnesis and a specific diagnosis, including instrumental analysis (e.g. hemodynamic cartography with eco-color Doppler), have been performed, the main strategy currently available for treating CVI therapeutically offers to adopt appropriate behavioral criteria aimed at ensuring a better lifestyle for the patient. The use of gradual and decreasing elastic compression, especially to address the obligatory sedentary lifestyle moments in daily life, accompanied by supplementary medical therapy aimed at obtaining a state of clinical and hemodynamic stabilization of the disease, certainly becomes the main strategy for treating CVI for the patient. The adoption of appropriate behavioral criteria, the synergistic collaboration between elastic compression and medical therapy makes it possible to obtain a stable state of the disease, by avoiding the progression of the disease and the development of complications. Even in the subsequent stages of the disease, the same treatment strategy is generally proposed in more invasive forms, with the aim of reducing its intensity, limiting the progression and development of complications, as well as curing the resulting aesthetic discomfort.
[0008] CVI medical therapy has developed over the past decades due to several experimental and clinical studies that have made it possible to elucidate the mechanisms underlying the disease, e.g. venous hypertension, blood congestion, inflammatory phenomena, tissue remodeling, degradation of matrix proteins.
[0009] Despite some progress made in understanding the mechanisms underlying the development of vascular diseases such as CVI, there remains a great need to find effective strategies of therapeutic treatment that make it possible not only to guarantee a better quality of life and stabilization of the clinical picture of the patient, but also to prevent complications associated therewith or even to ensure a better ability to accelerate the healing of the complications. Summary of the Invention
[0010] The object of the present invention is to provide a composition for oral use that is particularly effective in treating vascular disease and preventing its complications.To this end, the present invention provides a composition for oral use that comprises sulodexide and one or more flavonoids.According to a preferred embodiment, the composition of the present invention comprises one or more flavonoids selected from diosmin, hesperidin, troxerutin, oxerutin, quercitin and hesperidin.
[0011] The authors of the present invention have found that a specific combination of the active ingredient sulodexide with one or more flavonoids in an oral formulation is surprisingly more effective in treating vascular diseases such as CVI and preventing complications associated therewith than a single active ingredient.
[0012] The action of the composition to which the present invention relates has been evaluated by in vitro and in vivo tests, and the results have indeed highlighted that it is particularly effective in the treatment of vascular diseases, not due to a single active ingredient, but due to the synergistic action of its components used in conjunction.
[0013] In particular, the results obtained by the inventors in an animal model of CVI presented in the experimental section herein (Example 2) demonstrated the surprising ability of the compositions to which the invention relates to restore microvascular alterations in treated animals with efficacy greater than that determined for any single active ingredient present in the composition administered alone.
[0014] Furthermore, the data obtained from the in vitro and in vivo tests carried out by the authors of the present invention and presented in the experimental section of this specification have surprisingly demonstrated that the compositions to which the present invention relates make it possible to obtain greater efficacy in the treatment of vascular diseases than the active ingredients administered alone, even when the single active ingredients are present in the composition in dosages lower than those used for the administration of single molecules, due to the synergistic effect between the active ingredients present therein.
[0015] Therefore, the association between sulodexide and one or more flavonoids in oral preparations in the medical treatment of CVI makes it an effective therapeutic solution both in the early and more severe stages of the disease.Advantageously, the use of the composition according to the present invention is advisable not only in the purely conservative process of the disease associated with a sufficient standard of living and gradual elastic compression, but even in the stage of the "invasive" management of the disease as an adjuvant.In other words, the composition according to the present invention has great potential in the treatment of varicose vein syndrome and the management of trophic lesions from the "conservative" and "ablative" point of view, and for its treatment, the use of pharmacological therapy can accelerate the disappearance time of ulcers.
[0016] Effective medical therapy, such as that proposed by the present authors, can fully support the application of appropriate behavioral criteria and graded elastic compression already at the beginning of chronic venous insufficiency (C0s-C3). As with "direct" ablative or conservative therapy of varicose vein syndromes, and even in more advanced stages (C4-C6) that characterize chronic venous insufficiency, such medical therapy can bring a better quality of life for patients, a stabilization of the clinical picture, a better prognosis, and a great assistance in accelerating the healing of venous ulcers.
[0017] Thus, the combination of sulodexide with one or more flavonoids, in particular diosmin, in the same oral administration makes it possible to broaden the scope of action and effectiveness of medical therapy for vascular diseases, further accompanying better therapeutic adherence of patients and ensuring that it becomes the "best medical therapy".
[0018] Thus, the present invention provides - a composition for oral use comprising sulodexide and one or more flavonoids; - a composition according to any one of the embodiments described herein for use in the treatment of vascular diseases and / or the prevention of complications associated therewith; Regarding.
[0019] Further advantages, as well as features and modes of use of the present invention will become apparent from the following detailed description of some preferred embodiments, given purely by way of example. [Brief description of the drawings]
[0020] [Figure 1] FIG. 1 shows the effect of various treatments specified in Example 1 on vascular endothelial growth factor (VEGF)-induced hyperpermeability of human microvascular endothelial cell (HMVEC) monolayers. [Diagram 2] FIG. 1 shows the effect of the various treatments specified in Example 1 on VEGF-induced hyperpermeability of monolayers of human umbilical vein endothelial cells (HUVEC). [Diagram 3] Figure 1 shows the effect of the different treatments specified in Example 2 on venous inflammation. Assessment of leukocyte rolling: Leukocytes were labelled with rhodamine 6-G administered intravenously before observation. [Figure 4] FIG. 1 shows the effect of the various treatments specified in Example 2 on functional capillary density (meaning blood velocity in the microvessels and correlates with the distance traveled by red blood cells). [Diagram 5] FIG. 1 shows the effect of the various treatments specified in Example 2 on venular diameter assessed by intravital microscopy. [Figure 6] FIG. 1 shows the effect of the various treatments specified in Example 3 on the percentage of recovery of maximum venous contractility to noradrenergic stimulation under conditions of hyperthermia (41° C.). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] term Terms used herein are as commonly understood by those of ordinary skill in the art unless otherwise specified.
[0022] The term "chronic venous insufficiency", in the context of the present invention, abbreviated to CVI, has the meaning commonly used in medical practice. Chronic venous insufficiency is a disease characterized by a progressive decrease in vascular function, especially in the lower limbs, which in the long term determines the development of pain, edema and inflammation. Such a disease is characterized by alterations in the homeostasis of the microvascular tissue, with the resulting release of inflammatory mediators, fluctuations in wall tension and venous pressure that are involved in increased vascular permeability and decreased venous tone.
[0023] For a standardized description of the clinical picture and symptoms of CVI, reference is made to the clinical classification system commonly denoted by the acronym "CEAP" (Clinical, Etiology, Anatomy, Pathophysiology).
[0024] According to such a system, the various stages of the disease can be designated as follows: C0s: symptoms without evidence of disease; C1: reticular varicose veins and telangiectasias; C2: varicose veins; C3: edema; C4: lipodermatosclerosis; C5: healed ulcer; C6: active ulcer.
[0025] The expression "composition for oral use", in the context of the present invention, relates to a composition for oral administration to a subject in need thereof and therefore includes a composition according to any one of the embodiments described herein in any form known to a person skilled in the art that results in a composition suitable for oral administration.
[0026] As mentioned above, the present invention relates to a composition for oral use comprising sulodexide and one or more flavonoids.
[0027] As clearly highlighted by the results of the studies presented in the experimental section herein (Examples 2 and 3), the inventors have found and demonstrated that the compositions to which the present application relates have significant efficacy in treating microvascular alterations deriving from the selectivity of action of its active ingredients as well as the synergistic effect of their combination.
[0028] Sulodexide is a biological drug of natural origin, purified by porcine intestinal mucosa, consisting of a defined mixture of glycosaminoglycans (GAGs) consisting of 80% low molecular weight heparin and the remaining 20% dermatan sulfate (DS). It is characterized by a complex pharmacological profile, with several effects on the vasculature: antithrombotic, profibrinolytic, direct anti-inflammatory against metalloproteinases 2 and 9 (MMP-2 and MMP-9), structural for reintegration of the glycocalyx and protective against the endothelium. The sulodexide usable in the composition of the invention can be prepared according to any one of the techniques known to those skilled in the art and can be present in the composition even in the form of its pharma- ceutically acceptable salts, solvates or hydrates.
[0029] Flavonoids represent a class of chemical compounds of natural origin that show a demonstrated direct action on interstitial connectivity and have profound effects on parietal tone, vascular permeability and inflammatory processes.
[0030] Most used flavonoids belong substantially to the group of flavones and derivatives.Accordingly, according to a preferred embodiment, one or more flavonoids that can be used in the composition according to any one of the embodiments described herein are flavones or their derivatives, such as directly (e.g., diosmin, flavone) or indirectly as substantial derivatives (e.g., hesperidin, reduced flavone; troxerutin, hydroxyflavone).
[0031] The flavonoids that can be used in the compositions to which the present invention relates can be traced back to the family of "flavones and / or derivatives", even though each flavonoid belongs to a particular subfamily.
[0032] The chemical structure of a flavone is a carbon atom skeleton C consisting of two aromatic rings and one heterocyclic ring, in which one aromatic ring (ring A) is fused to a heterocyclic ring (ring C) and a third aromatic ring (aromatic ring B) is bonded to ring C at the 2-position. 15 Includes.
[0033] Flavones are soluble in water and ethanol and exhibit a characteristic yellow color when dissolved in alkaline solution.
[0034] The expressions "derivatives" or "flavone derivatives" as used in the context of the present invention therefore relate to compounds belonging to the family of flavonoids, characterized by or obtained starting from chemical modifications and / or substitutions of the basic chemical structure of flavone.
[0035] The one or more flavonoids that can be used in the composition according to any one of the embodiments described herein can be obtained starting from plant material, e.g. plants, by using any one of the techniques known to the person skilled in the art.
[0036] According to one embodiment of the invention, the one or more flavonoids are preferably selected from among diosmin, hesperidin, troxerutin, oxerutin, quercitin and hesperidin, preferably from among diosmin, hesperidin and troxerutin.
[0037] Diosmin is a polyhydroxylated flavone with eight hydroxyl groups, two of which are phenolic, is widely distributed in the plant kingdom and has the following structure: [ka]
[0038] Citrus fruits (lemon, orange, grapefruit, etc.), Bucco leaves (Barosma betulina) and the flower tops of Ruta (Ruta graveolens) contain significant concentrations of geosmin.
[0039] Hesperidin is a flavone derivative belonging to the subfamily of flavanones, or a type of flavonoid that can be found inside the fruit, especially of citrus fruits, characterized by strong antioxidant, capillarotropic and vasoprotective properties, and has the following structure: [ka]
[0040] Chemically, troxerutin is a hydroxyethyl rutoside, a derivative of rutin, having the following structure: [ka]
[0041] Such compounds are flavone derivatives that can be isolated from the Sophora japonica (Japanese pagoda tree), but are also present in tea, coffee, cereals, and many types of fruits and vegetables.
[0042] The diosmin, hesperidin and / or troxerutin that can be used in any one of the compositions described herein can be of synthetic or natural origin.In the compositions of the present invention, plant extracts or plant parts that contain one or more flavonoids, such as diosmin, hesperidin and / or troxerutin, such as plant extracts that contain defined flavonoid names, preferably expressed as weight percentages relative to the total extract, can also be used.In the prior art, plant extracts that contain one or more flavonoids, such as diosmin, hesperidin troxerutin, oxerutin, quercitin and / or hesperidin, are known.
[0043] Those skilled in the art can adapt, as required, the amounts of sulodexide and one or more flavonoids used in the preparation of the compositions of the invention.
[0044] According to a preferred aspect of the invention, sulodexide is present in the composition according to any one of the embodiments described herein in an amount comprised between 21 mg and 29 mg, preferably equal to 25 mg.
[0045] The concentration of sulodexide can be expressed in lipoprotein lipase releasing units (or lipasemic units): such units, which measure the biological activity of sulodexide, are based on the ability of this active ingredient, when injected intravenously into rats, to release into the blood the clearing factor or beta lipoprotein lipase, a lytic enzyme that attacks only protein-bound triglycerides. 1 mg of sulodexide corresponds to 10 ULS. Preferably, sulodexide is present in the composition according to any one of the embodiments described herein in an amount equivalent to 250 ULS (lipasemic units).
[0046] According to one aspect of the invention, the one or more flavonoids, in particular the one or more flavones and / or derivatives thereof, are present in the composition according to any one of the embodiments described herein in an amount comprised between 380 mg and 520 mg, preferably equal to 450 mg.
[0047] The inventors have found the optimal pro-dose (or single dose unit) dosage of each substance of the composition of the present invention to obtain a synergistic therapeutic effect. In particular, the best effect is obtained when sulodexide is present in an amount equal to 25 mg and said one or more flavonoids are present in an amount equal to 450 mg.
[0048] From the experiments carried out, the inventors have found that the combination of sulodexide and diosmin in a formulation for oral use is surprisingly more effective than the single active ingredients administered alone.
[0049] Thus, a preferred embodiment according to the invention relates in particular to a composition for oral use comprising sulodexide and diosmin.Preferably, this preferred composition comprises sulodexide in an amount equal to 25 mg by weight and diosmin in an amount equal to 450 mg by weight.
[0050] According to a preferred embodiment, the composition of the present invention comprises a pre-established association between sulodexide and one or more flavonoids according to any one of the embodiments described herein.By way of pure example, the composition of the present invention can be obtained through a process of mixing at least sulodexide according to any one of the embodiments described herein with one or more flavonoids to obtain the pre-established association of the above-mentioned active ingredients.
[0051] The present invention also relates to a composition according to any one of the embodiments described herein, further comprising one or more suitable excipients.
[0052] Suitable excipients may be selected from among those commonly known in the prior art, including, but not limited to: carriers (e.g., soybean oil), diluents, lubricants (e.g., magnesium stearate, stearic acid, waxes), dispersants, surfactants or surface active substances (e.g., sodium lauryl sulfate and polysorbates), flavoring agents, adsorbents (e.g., silica gel, talcum, starch, bentonite, kaolin), glidants and anti-adherents (e.g., talcum, colloidal silica, corn starch, silicon dioxide), colorants (e.g., iron oxide), opacifiers (e.g., titanium dioxide), antioxidants, binders (e.g., ethylhexyl ether ... For example, gums, starches, gelatins, cellulose derivatives, sucrose, sodium alginate), disintegrants (starch, microcrystalline cellulose, alginic acid, crospovidone), plasticizers or plasticizers (e.g., ethyl cellulose and other cellulose derivatives, acrylates and methacrylates, glycerol and sorbitol), preservatives (e.g., parabens, sulfur dioxide, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate), viscosifiers, thickeners (e.g., beeswax), emulsifiers, humectants, humectants, chelating agents and mixtures thereof.
[0053] According to a preferred aspect of the present invention, said sulodexide and said one or more flavonoids are active ingredients of the composition in any one of the embodiments described herein.
[0054] The term "active ingredient" in the context of the present invention refers to the fact that sulodexide and said one or more flavonoids are present within the composition according to the invention in an amount effective to obtain the desired therapeutic effect in a subject undergoing a therapeutic treatment providing for the administration of said composition.
[0055] A preferred embodiment according to the present invention relates in particular to a composition for oral use according to any one of the embodiments described herein, wherein said sulodexide and said one or more flavonoids are the only active ingredients of the composition.
[0056] However, in accordance with additional aspects of the present invention, the compositions of the present invention may, optionally, further comprise one or more additional active ingredients.
[0057] The composition of the present invention can be in any pharma- ceutically acceptable form known to those skilled in the art, so long as it is suitable for oral administration.
[0058] The compositions of the present invention may be, for example, in solid, liquid or gel form, such as a tablet, hard capsule, soft capsule, suspension, emulsion, solution.
[0059] A preferred embodiment according to the invention relates to a composition in the form of a soft capsule, having a quali-quantitative composition as shown in Table 1 below. [Table 1]
[0060] According to one aspect of the invention, the composition of any one of the embodiments described herein is a pharmaceutical composition.
[0061] As mentioned above, the present invention also relates to a composition according to any one of the embodiments described herein for use in the treatment of vascular diseases and / or the prevention of complications associated with or caused by these diseases, in particular the treatment of chronic venous insufficiency and / or the prevention of its complications (including skin pigmentation up to venous ulcers) and / or symptoms or disorders associated with or caused by this disease, among others post-thrombotic syndrome.
[0062] According to one aspect of the present invention, the composition according to any one of the embodiments described herein is a composition for use in the treatment of chronic venous insufficiency of the legs and / or the treatment of symptoms or disorders associated with or caused by this disease, and / or the prevention of complications associated with or caused by this disease.In the context of the present invention, the term "symptoms" or "disorders" associated with or caused by chronic venous insufficiency also includes complications associated with or resulting from this disease, among which are the symptoms and / or disorders exemplified below.
[0063] Examples of symptoms, disorders or complications that may be related to vascular disease, particularly chronic venous insufficiency, or may be caused by these diseases are selected from edema, difficulty in movement, burning sensation, itching, paresthesia or tingling, pain, muscle spasms, swelling sensation, heaviness in the legs, restless legs syndrome, leg fatigue, postphlebitic syndrome, congestion dermatitis and bruising, thrombotic and phlebitis process, lipodermatosclerosis, trophic lesion.The ability of the composition according to any one of the embodiments described herein to treat the symptoms or disorders caused by chronic venous insufficiency exemplified herein and / or prevent the onset of their complications is the result of the synergistic action of the active ingredients associated in the above-mentioned composition. Indeed, the compositions to which the present invention relates, by determining an effective reduction of vascular hyperpermeability and infiltration by inflammatory molecules and the restoration of venous tone (as will be clearly emphasized below), actually eliminate or contribute to the elimination of causes associated with or contributing to the development of the complications or symptoms in question, thus making it possible to prevent and / or treat such disorders or at least aid in the treatment of such disorders and / or the prevention of their complications.
[0064] The treatment or prevention of complications according to the present invention comprises at least administering the composition according to any one of the embodiments described herein to a subject in need thereof.Subjects suitable for treatment with the composition according to the present invention are therefore particularly those who have been diagnosed with a vascular disease or have been determined to be at high risk of developing a vascular disease, such as any one of the diseases described in the text and / or claims herein, and symptoms or disorders associated therewith or caused by them.
[0065] The present invention also relates to a composition according to any one of the embodiments described herein for use in a method for the treatment of vascular diseases and complications associated with or caused by these diseases, in particular CVI or the prevention of symptoms, complications or disorders associated with or caused by said diseases, wherein the method at least comprises the step of administering said composition by the oral route to a subject in need thereof.
[0066] Dosages and treatment regimens of the compositions according to the invention can be established by the treating physician based on the weight, health, sex and age of the subject being treated, and can be modified over time based on the subject's response to the therapeutic treatment.
[0067] Thus, the dosage of the single active ingredients in the composition according to the invention can be adapted depending on the results obtained over time, even during the period of taking the composition according to the invention.
[0068] According to one aspect of the invention, a composition according to any one of the embodiments described herein may be administered to a subject in need thereof in one or more doses at a daily dosage comprised between 475-950 mg / day.
[0069] Preferably, the compositions of the present invention are administered to a subject in need thereof, for example, at least once daily, preferably twice daily.
[0070] The compositions to which the present invention pertains can be prepared by mixing the selected active ingredient with other possible excipients as known to those skilled in the art.
[0071] Also described herein is a therapeutic method for the treatment of vascular disease and / or prevention of complications associated therewith, particularly chronic venous inflammation and symptoms or disorders associated therewith or caused thereby, comprising administering to a subject in need thereof a therapeutically effective dosage of a composition according to any one of the embodiments described herein.
[0072] The administration of the composition according to the invention can be repeated several times a day, the composition can already be provided in single dose form or with a single dose dispenser.
[0073] "Therapeutically effective dose" means a therapeutically effective dose or an amount sufficient to provide a desired therapeutic effect. A therapeutically effective dose is an amount that produces one or more desired biological activities during the treatment or prevention of disease. In this case, during the treatment of vascular disease and its complications, particularly chronic venous inflammation or the symptoms or disorders associated therewith or caused therewith. Examples of disorders or symptoms associated with or caused by chronic venous insufficiency are those already defined above with respect to the medical use of the composition of the present invention.
[0074] Examples are provided below for the purpose of better illustrating the methods disclosed herein, but such examples should in no way be construed as limiting the scope of the preceding description and subsequent claims.
[0075] example Example 1. In vitro studies of human microvascular and macrovascular cell cultures The direct effect of three compositions containing sulodexide + flavonoids on vascular permeability was evaluated in vitro: (i) Sulodexide + Diosmin (Sul+Dios), (ii) Sulodexide + hesperidin (Sul+Esp); (iii) Sulodexide + Troxerutin (Sul+Trox).
[0076] All compositions (i) to (iii) tested contain sulodexide in a concentration equal to 0.25% by weight relative to the total weight of the composition, and diosmin, hesperidin or troxerutin in a concentration equal to 4.5% by weight, respectively.
[0077] The effects of compositions (i)-(iii) were compared with those of the active ingredients diosmin, hesperidin, troxerutin, 8% by weight, and the glycosaminoglycan sulodexide, 0.5% by weight, administered alone.
[0078] Direct effects on vascular permeability were evaluated by using endothelial cell cultures that mimic a continuous monolayer of the endothelium of human blood vessels. Two cell models were used: human microvascular endothelial cells (HMVEC) to simulate the blood vessels of the microcirculation, and human umbilical vein endothelial cells (HUVEC) to study the vasal endothelium. HMVEC and HUVEC lines (3 × 10 5 ) cells were incubated for 72 hours at 37° C. on a semi-permeable membrane support with pores of 1 μm diameter. Vascular permeability was evaluated with the kit "The Millipore® In Vitro Vascular Permeability Assay".
[0079] The monolayers were treated with the permeability inducer vascular endothelial growth factor (VEGF) for 8 hours. At a concentration of 50 ng / ml, VEGF induced an increase in permeability of 36% in HMVEC lines and 42% in HUVEC cells, corresponding to the highlightable CVI clinical picture. The two monolayers were then incubated for 8 hours with 100 ng / ml of (i) sulodexide + diosmin (Sul+Dios), (ii) sulodexide + hesperidin (Sul+Esp), (iii) sulodexide + troxerutin (Sul+Trox), (iv) diosmin, (v) hesperidin, (vi) troxerutin and (vii) sulodexide alone.
[0080] The concentrations tested were chosen based on preliminary experiments aimed at eliminating possible interference with cell vitality and proliferation. FITC-dextran was then introduced. Endothelial permeability, assessed by a fluorometer as the concentration of FITC-dextran across the barrier formed by the cell monolayer, was tested.
[0081] result At the end of the study, the following was highlighted: Treatment with VEGF for 8 hours induced a statistically significant increase in permeability compared to untreated controls (basal) for both cell models tested (p<0.0001).
[0082] Surprisingly, the association of sulodexide + flavonoids (i.e. compositions (i)-(iii)), even though it contained lower concentrations of the active ingredients than those administered alone, restored the VEGF-induced increase in vascular permeability in both endothelial models (p<0.0001), with a statistically significant difference compared to the flavonoids and sulodexide administered alone (p<0.01).
[0083] Among the various compositions tested that contained sulodexide + flavonoids, the composition containing sulodexide + diosmin (Sul+Dios) highlighted a surprisingly large effect on the reduction of vascular hyperpermeability when compared to that exerted by the other compositions (statistically significant difference p<0.05; results are shown in Figures 1 and 2).
[0084] Comparison with the administration of various molecules tested alone revealed a synergistic effect of the association of sulodexide + diosmin on the reduction of altered vascular hyperpermeability. Without being bound by theory, such results may be related to a synergistic effect between the mechanism of action of sulodexide, such as the restoration of membrane glycocalyx, the reduction of vascular hyperpermeability and the reduction of infiltration of inflammatory molecules, and that of diosmin, which increases the available adrenaline levels through the inhibition of the catechol-o-methyltransferase (COMT) enzyme and therefore its vasoconstrictor effect on edema.
[0085] Example 2. In vivo studies in animal models of chronic venous insufficiency The treatment described in Example 1 was tested in an experimental study carried out on an animal model of chronic venous insufficiency, which made it possible to evaluate in vivo, via oral administration, the effect of such a composition on the microvascular changes in response to increased venous pressure: 18 male hamsters (Mesocricetus auratus) weighing 85-120 gr were subjected to venous ligation and randomized into 9 groups, each treated by the oral route with a composition based on: 1. 0.25% Sulodexide + 4.5% Diosmin in 10% lactose solution (Sul+Dios); 2. 0.25% Sulodexide + 4.5% Hesperidin in 10% lactose solution (Sul+Esp); 3. 0.25% sulodexide + 4.5% troxerutin in 10% lactose solution (Sul+Trox); 4. 8% diosmin in 10% lactose solution; 5. 8% hesperidin in 10% lactose solution; 6. Troxerutin 8% in 10% lactose solution; 7. 0.5% sulodexide in 10% lactose solution; 8. 10% lactose solution (placebo group); 9. Health status check, not having undergone venous ligation or treatment.
[0086] After anesthesia by intraperitoneal injection (xylazine 10 mg / kg + ketamine 200 mg / kg), the animals were subjected to inguinal incision followed by venous ligation by using a suture at the third level of the right external iliac vein. Such an experimental model of chronic venous insufficiency produces in the animals a significant increase in leukocyte-endothelial interactions, microvascular dysfunction and reduced tissue blood perfusion, a decrease in functional capillary density (FCD), an increase in venular diameter and an increase in inflammatory processes in the hind limbs that correlate with impaired function of vascular smooth muscle cells.
[0087] All formulations tested were dissolved in 10% lactose solution and administered twice daily via oral probe at a volume of 0.2 mL / 100 gr body weight and at a concentration of 100 mg / kg / day. The various treatments were performed 2 weeks before and 6 weeks after vein ligation.
[0088] Intravital microscopy coupled to a camera was used to assess microvascular changes such as arteriolar and venular diameters, functional capillary density (using fluorescein isothiocyanate-dextran-FITC-dextran), labeling circulating leukocytes and rolling, and adhesion of leukocytes to the endothelium by video recording (leukocytes were considered rolling when in contact with the venular wall and slower than circulating erythrocytes, and adherent when fixed in the same position for at least 30 s).
[0089] result The results confirmed the following: All animals subjected to vein ligation had an inflammatory state expressed as a significantly higher circulating leukocyte count, a decrease in functional capillary density (FCD) and an increase in venular diameter than the control group (p<0.001).
[0090] All the treatments tested were accompanied by a reduction in circulating white blood cells. Surprisingly, the reduction obtained in the group treated with the composition containing sulodexide + flavonoids was higher than that obtained with diosmin, hesperidin, troxerutin and sulodexide administered alone (p<0.001), even when lower concentrations of the active ingredients were used than those of the active ingredients tested alone. A higher reduction was highlighted in the group treated with Sul+Dios, even if it was not statistically significant, compared to those highlighted in the other two associations (Figure 3).
[0091] Surprisingly, it was found that the group treated with the composition containing Sulodexide + flavonoids showed less FCD reduction, with a statistically significant difference compared to the groups treated with Diosmin, Hesperidin, Troxerutin and Sulodexide administered alone (p<0.001). The group treated with Sul+Dios demonstrated a significant reduction and prevention of FCD reduction, with a statistically significant difference compared to the other association, Sulodexide + flavonoids (p<0.01) (Figure 4).
[0092] · Venular diameter was significantly reduced in the group treated with the composition containing Sulodexide + flavonoids compared to the other treatments (p<0.001). The group treated with Sul+Dios had a statistically significant reduction in venular diameter compared to all other treatment groups (p<0.01) (Figure 5).
[0093] It was demonstrated that oral treatment with a composition containing sulodexide + flavonoids was effective in restoring microvascular changes in this animal model of chronic venous insufficiency, showing a higher efficacy compared to the same evaluated molecules administered alone. Surprisingly, a more pronounced efficacy was found in the group treated with sulodexide + diosmin. Such evidence emphasizes the synergistic action of sulodexide + diosmin treatment by confirming what was already seen in the preceding in vitro model.
[0094] Example 3. Ex vivo study on human saphenous vein Due to the experimental results obtained, a study was carried out on saphenous veins to investigate the direct effect on venous tone of compositions containing sulodexide + diosmin (Sul+Dios), sulodexide + hesperidin (Sul+Esp) and sulodexide + troxerutin (Sul+Trox) (all expressed by weight relative to the total weight of the composition, at concentrations equal to 0.25% sulodexide and 4.5% flavonoids, respectively) by evaluation of the effect on the contractile response to noradrenaline of compositions containing sulodexide + diosmin (Sul+Dios), sulodexide + hesperidin (Sul+Esp) and sulodexide + troxerutin (Sul+Trox). Such effect was compared with that of the active ingredients 8% diosmin, hesperidin, troxerutin and 0.5% sulodexide administered alone.
[0095] Venous fragments were collected through a simple incision in the varicose region of the saphenous or collateral veins from subjects suffering from varicose vein disease subjected to local anesthesia. The fragments were kept for 24-48 hours in Krebs-Henseleit's solution at 4°C and pH 7. Venous rings 3-4 mm in length were subjected to isometric contractions (tension of about 1 gr). After a stabilization step, the responsiveness of the rings to a high potassium stimulus [50 mM, about 2 hours] was verified. Under conditions of constant hyperthermia (41°C), some preparations under analysis were incubated for 10 min. -4 The mixture was incubated for 30 min at a concentration of 10 M. Then, a cumulative concentration of noradrenaline (10 -6 For each ring, the results were expressed as a percentage of the maximum response to noradrenaline (agonist) and a dose / effect curve was determined at a temperature of 41°C.
[0096] Statistical analysis of the results demonstrated that the Sulodexide + flavonoid association restored venous tone at 41 °C by enhancing the contractile response of the venous rings to noradrenaline, the difference in percentage of recovery being statistically significant (p<0.001) compared to the various substances administered alone, even if they contained significantly lower concentrations of active ingredients than the concentrations of the same active ingredients tested alone. Furthermore, the Sul+Dios association demonstrated a greater effect on venous tone and, surprisingly, the percentage of venous tone recovery was statistically significantly different (p<0.01) compared to the other associations. Figure 6 shows the details of the results obtained.
[0097] The results confirm that associating Sulodexide with the flavonoids (diosmin, hesperidin and troxerutin) guarantees a synergistic effect on venous tone. Among the various tested compositions, the combination Sulodexide + diosmin demonstrated the most remarkable effect. Without wishing to be associated with theories, it is speculated that such results stem from the synergistic effect of Sulodexide and diosmin, two active ingredients that both act on venous tone by two different mechanisms of action. Sulodexide exerts its phlebotonic action by increasing vasoconstriction through the inhibition of metalloproteinases 2 and 9, while diosmin exerts its phlebotonic action through the inhibition of the catechol-o-methyltransferase enzyme and the resulting reduction in the metabolism of noradrenaline (NA). Thus, the increase in the available NA concentration at the level of vascular adrenergic receptors prolongs the vasoconstrictive and venous tone effects.
Claims
1. A composition for oral use comprising sulodexide and one or more flavonoids.
2. 2. The composition for oral use according to claim 1, wherein the one or more flavonoids are flavones or derivatives thereof.
3. 3. The composition according to claim 1 or 2, wherein the one or more flavones or derivatives thereof are selected from diosmin, hesperidin, troxerutin, oxerutin, quercetin and hesperitin.
4. A composition according to any one of claims 1 to 3, comprising sulodexide and diosmin.
5. 5. The composition according to any one of claims 1 to 4, in the form of a tablet, hard capsule, soft capsule, suspension, emulsion or solution.
6. The composition according to any one of claims 1 to 5, wherein said sulodexide is comprised between 21 and 29 mg, preferably in an amount equal to 25 mg.
7. The composition according to any one of claims 1 to 6, wherein the one or more flavonoids are comprised between 380 and 520 mg, preferably in an amount equal to 450 mg.
8. 8. The composition of claim 1 , comprising a plant extract containing one or more flavonoids.
9. 9. The composition of claim 1, wherein said sulodexide and said one or more flavonoids are active ingredients of said composition.
10. 10. The composition of claim 1, further comprising one or more pharma- ceutically acceptable excipients.
11. 11. A composition according to any one of claims 1 to 10 for use in the treatment of vascular diseases and / or the prevention of complications associated with or caused by these diseases.
12. 12. The composition for use according to claim 11, wherein the vascular disease comprises chronic venous insufficiency and / or symptoms or disorders associated with or caused by chronic venous insufficiency.
